0001209191-20-054346.txt : 20201008 0001209191-20-054346.hdr.sgml : 20201008 20201008191021 ACCESSION NUMBER: 0001209191-20-054346 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201008 FILED AS OF DATE: 20201008 DATE AS OF CHANGE: 20201008 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Loven Jakob CENTRAL INDEX KEY: 0001753644 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39592 FILM NUMBER: 201231818 MAIL ADDRESS: STREET 1: C/O ARVINAS, INC., 5 SCIENCE PARK STREET 2: 395 WINCHESTER AVENUE CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kronos Bio, Inc. CENTRAL INDEX KEY: 0001741830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 1300 S. EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN MATEO STATE: CA ZIP: 94402 BUSINESS PHONE: 212-871-7920 MAIL ADDRESS: STREET 1: 1300 S. EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN MATEO STATE: CA ZIP: 94402 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-10-08 0 0001741830 Kronos Bio, Inc. KRON 0001753644 Loven Jakob C/O KRONOS BIO, INC. 1300 SO. EL CAMINO REAL, SUITE 300 SAN MATEO CA 94402 1 0 0 0 Series A Preferred Stock Common Stock 1376313 I See footnote Convertible Promissory Note 16.15 2022-02-20 Common 169031 I See footnote Each share of Series A Preferred Stock (the "Preferred Stock") is convertible into 1.055 shares of Common Stock. The Preferred Stock has no expiration date. Represents shares of common stock issuable upon conversion of preferred stock held by Nextech V Oncology S.C.S, SICA-SIF ("Nextech V"). The reporting person currently serves as a member of the leadership team at Nextech Invest AG ("Nextech AG"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. The convertible promissory note will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's first firm commitment underwritten initial public offering. /s/ David Tanen, Attorney-in-fact 2020-10-08 EX-24.3_940990 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of David Tanen, Yasir Al-Wakeel, Barbara Kosacz and Allison Frisbee of Kronos Bio, Inc. (the "Company"), signing individually, the undersigned's true and lawful attorney-in fact and agent to: (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 2nd day of October 2020. /s/ Jakob Loven, Ph.D.